D. Stephens

发表

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Diane J Post, D. Montefiori, D. Szydlo, 2022, Cell Reports Medicine.

Homologous and Heterologous Covid-19 Booster Vaccinations

D. Montefiori, R. Coler, P. Roberts, 2022, The New England journal of medicine.

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

A. Falsey, D. Montefiori, S. Little, 2023, Research square.

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

Michael John Smith, E. Walsh, A. Falsey, 2022, medRxiv.

Vaccines at what price?

R. Ahmed, D. Stephens, W. Orenstein, 2014, Vaccine.

Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

N. Rouphael, D. Stephens, A. Dretler, 2018, Human vaccines & immunotherapeutics.

COVID-19 and the Path to Immunity.

M. McElrath, D. Stephens, D. Stephens, 2020, JAMA.

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

K. Schmader, E. Walsh, A. Falsey, 2023, Nature Medicine.

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

J. Wrammert, R. Ahmed, N. Rouphael, 2021, bioRxiv.

Homologous and Heterologous Covid-19 Booster Vaccinations

D. Montefiori, R. Coler, P. Roberts, 2022, New England Journal of Medicine.